<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031742</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI306A201</org_study_id>
    <nct_id>NCT04031742</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia</brief_title>
  <official_title>Phase 2b/3 Study to Assess the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia. Part 1 - Open-label, Two-arm, Multicenter Pilot Study to Evaluate Efficacy and Safety of IBI 306 in Subjects With Homozygous Familial Hypercholesterolemia. Part 2 - Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of IBI 306 in Subjects With Homozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate safety and efficacy of IBI306 in subjects with homozygous familial
      hypercholesterolemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: open-label, two-arm, randomized, multicenter. Part 2: open-label, single-arm,
      multicenter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2019</start_date>
  <completion_date type="Anticipated">April 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 [ Time Frame: Baseline and Week 12 ]</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C).</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Number of investigational product-related adverse events.</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of ADA and Nab.</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Part 1: IBI306</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received open-label IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: IBI306</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received open-label 450mg Q4W subcutaneously for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI306</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Part 1: IBI306</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI306</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Part 2: IBI306</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females ≥ 18 to ≤ 80 years of age

          2. Diagnosis of homozygous familial hypercholesterolemia

          3. LDL cholesterol ≥ 130 mg/dl (3.4mmol/L)

          4. Triglyceride ≤ 400 mg/dL (4.5 mmol/L)

          5. Bodyweight of ≥ 40 kg at screening.

        Exclusion Criteria:

          1. Liver transplant history.

          2. Uncontrolled hypertension.

          3. Moderate to severe renal dysfunction.

          4. Active liver disease or hepatic dysfunction.

          5. Known sensitivity to any of the products to be administered during dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wenjing duan</last_name>
    <phone>0512-69566088</phone>
    <email>wenjing.duan@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital， Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lvya wang</last_name>
      <phone>010-64456464</phone>
      <email>wangluya@126.com</email>
    </contact>
    <contact_backup>
      <last_name>yang lin</last_name>
      <phone>010-64456464</phone>
      <email>lingyang2623@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

